Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed sim...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-10-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1010-660X/55/10/707 |
| _version_ | 1797728424908816384 |
|---|---|
| author | Oronzo Brunetti Antonio Gnoni Antonella Licchetta Vito Longo Angela Calabrese Antonella Argentiero Sabina Delcuratolo Antonio Giovanni Solimando Andrea Casadei-Gardini Nicola Silvestris |
| author_facet | Oronzo Brunetti Antonio Gnoni Antonella Licchetta Vito Longo Angela Calabrese Antonella Argentiero Sabina Delcuratolo Antonio Giovanni Solimando Andrea Casadei-Gardini Nicola Silvestris |
| author_sort | Oronzo Brunetti |
| collection | DOAJ |
| description | Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed similar results in terms of survival in a non-inferiority randomized trial study considering the same subset of patients. Unlike other targeted therapies, predictive and prognostic markers in HCC patients treated with sorafenib are lacking. Their identification could help clinicians in the daily management of these patients, mostly in light of the new therapeutic options available in the first. |
| first_indexed | 2024-03-12T11:13:46Z |
| format | Article |
| id | doaj.art-8beff8d04d66496491213f416793988a |
| institution | Directory Open Access Journal |
| issn | 1010-660X |
| language | English |
| last_indexed | 2024-03-12T11:13:46Z |
| publishDate | 2019-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-8beff8d04d66496491213f416793988a2023-09-02T02:28:27ZengMDPI AGMedicina1010-660X2019-10-01551070710.3390/medicina55100707medicina55100707Predictive and Prognostic Factors in HCC Patients Treated with SorafenibOronzo Brunetti0Antonio Gnoni1Antonella Licchetta2Vito Longo3Angela Calabrese4Antonella Argentiero5Sabina Delcuratolo6Antonio Giovanni Solimando7Andrea Casadei-Gardini8Nicola Silvestris9Medical Oncology Unit, National Cancer Research Centre, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, ItalyMedical Oncology Unit, “S. Cuore di Gesù” Hospital, 73014 Gallipoli, ItalyMedical Oncology Unit, “S. Cuore di Gesù” Hospital, 73014 Gallipoli, ItalyMedical Thoracic Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, ItalyRadiology Unit, National Cancer Research Centre, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, ItalyMedical Oncology Unit, National Cancer Research Centre, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, ItalyScientific Direction, National Cancer Research Centre, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, ItalyMedical Oncology Unit, National Cancer Research Centre, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, ItalyDepartment of Medical Oncology, IstitutoScientifico Romagnolo per Lo Studio e Cura Dei Tumori (IRST) IRCCS, 47014 Meldola, ItalyMedical Oncology Unit, National Cancer Research Centre, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, ItalySorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed similar results in terms of survival in a non-inferiority randomized trial study considering the same subset of patients. Unlike other targeted therapies, predictive and prognostic markers in HCC patients treated with sorafenib are lacking. Their identification could help clinicians in the daily management of these patients, mostly in light of the new therapeutic options available in the first.https://www.mdpi.com/1010-660X/55/10/707sorafenibhepatocellular carcinomaprognostic factorspredictive factors |
| spellingShingle | Oronzo Brunetti Antonio Gnoni Antonella Licchetta Vito Longo Angela Calabrese Antonella Argentiero Sabina Delcuratolo Antonio Giovanni Solimando Andrea Casadei-Gardini Nicola Silvestris Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib Medicina sorafenib hepatocellular carcinoma prognostic factors predictive factors |
| title | Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib |
| title_full | Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib |
| title_fullStr | Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib |
| title_full_unstemmed | Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib |
| title_short | Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib |
| title_sort | predictive and prognostic factors in hcc patients treated with sorafenib |
| topic | sorafenib hepatocellular carcinoma prognostic factors predictive factors |
| url | https://www.mdpi.com/1010-660X/55/10/707 |
| work_keys_str_mv | AT oronzobrunetti predictiveandprognosticfactorsinhccpatientstreatedwithsorafenib AT antoniognoni predictiveandprognosticfactorsinhccpatientstreatedwithsorafenib AT antonellalicchetta predictiveandprognosticfactorsinhccpatientstreatedwithsorafenib AT vitolongo predictiveandprognosticfactorsinhccpatientstreatedwithsorafenib AT angelacalabrese predictiveandprognosticfactorsinhccpatientstreatedwithsorafenib AT antonellaargentiero predictiveandprognosticfactorsinhccpatientstreatedwithsorafenib AT sabinadelcuratolo predictiveandprognosticfactorsinhccpatientstreatedwithsorafenib AT antoniogiovannisolimando predictiveandprognosticfactorsinhccpatientstreatedwithsorafenib AT andreacasadeigardini predictiveandprognosticfactorsinhccpatientstreatedwithsorafenib AT nicolasilvestris predictiveandprognosticfactorsinhccpatientstreatedwithsorafenib |